Sec. 5. This chapter does not create a cause of action against a manufacturer of an investigational drug, biological product, or device for any harm to a qualified patient resulting from use of an investigational drug, biological product, or device. IC 16-42-26.5 Chapter 26.5. Individualized Investigational Treatment 16-42-26.5-1 "Eligible facility" 16-42-26.5-2 "Individualized investigational treatment" 16-42-26.5-3 "Life threatening or severely debilitating disease" 16-42-26.5-4 Qualification requirements 16-42-26.5-5 Written informed consent 16-42-26.5-6 Availability of individualized investigational treatment 16-42-26.5-7 Liability for outstanding debt 16-42-26.5-8 Prohibition on disciplinary actions for recommending individualized investigational treatment 16-42-26.5-9 Effect on clinical trial laws
‹ Prev All Indiana sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.